At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Histologically or cytologically confirmed ROS1 molecular fusion in locally advanced or metastatic solid tumors
- ✓Measurable disease by RECIST version 1.1
- ✓Life expectancy of at least 3 months
- ✕Current participation in another therapeutic clinical trial
- ✕Gastrointestinal disease or malabsorption syndromes affecting drug absorption
- ✕History of severe allergies or hypersensitivity to study drug components
- ✕Known active infections including bacterial, viral, and HIV
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating JYP0322 50 mg qd, JYP0322 100 mg qd, and 5 other interventions for Protein Kinase Inhibitors and 3 related conditions. Currently recruiting, targeting 101 participants across 1 site.
Detailed Summary
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Study Details
Timeline
Interventions
JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.